(24/7 MARKET NEWS)– LAVA Therapeutics N.V. (NASDAQ: LVTX) is way up on news that it entered into an exclusive worldwide license agreement, with Seagen Inc. (NASDAQ: SGEN), to advance LAVA-1223.
The two companies stated that “LAVA to Receive Upfront Payment of $50 Million, With Potential for Milestones of up to Approximately $650 Million and Royalties”
After closing Friday’s session at $2.40, a 4-cent gain (+1.52%), on volume of 5,549 shares traded, LAVA Therapeutics is trading at $5.16, up $2.76 (+115.00%), on over 2 million premarket shares.
LAVA’s 52 week range is $2.28 to $8.38 and it’s challenging resistance from January and February.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.